Trial Profile

First-Line Osimertinib for Poor Performance Status Patients with EGFR Mutant Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osimertinib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms OPEN

Most Recent Events

08 Jul 2024 New trial record
04 Jun 2024 Primary endpoint has been met. (Objective response rate), according to results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com